Expert Outlook: Pacific Biosciences Through The Eyes Of 10 Analysts
Expert Outlook: Pacific Biosciences Through The Eyes Of 10 Analysts
專家展望：10位分析師眼中的太平洋生物科學
Pacific Biosciences (NASDAQ:PACB) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
太平洋生物科學公司（納斯達克股票代碼：PACB）在上個季度接受了10位分析師的分析，揭示了從看漲到看跌的一系列觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.4, a high estimate of $12.00, and a low estimate of $2.00. Experiencing a 50.56% decline, the current average is now lower than the previous average price target of $8.90.
分析師通過對12個月目標股價的評估提供了更深入的見解，顯示平均目標價爲4.4美元，最高估計爲12.00美元，低估值爲2.00美元。目前的平均價格下降了50.56％，現在低於之前的平均目標股價8.90美元。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
A comprehensive examination of how financial experts perceive Pacific Biosciences...
對金融專家如何看待太...
登入免費觀看全文
登入/註冊